Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Insights into Imaging
Published in: Insights into Imaging 1/2021

Open Access 01-12-2021 | Kaposi's Sarcoma-Associated Herpesvirus | Critical Review

Emerging role of 18F-FDG PET/CT in Castleman disease: a review

Authors: Benjamin Koa, Austin J. Borja, Mahmoud Aly, Sayuri Padmanabhan, Joseph Tran, Vincent Zhang, Chaitanya Rojulpote, Sheila K. Pierson, Mark-Avery Tamakloe, Johnson S. Khor, Thomas J. Werner, David C. Fajgenbaum, Abass Alavi, Mona-Elisabeth Revheim

Published in: Insights into Imaging | Issue 1/2021

Login to get access

Abstract

Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging.
Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://​clinicaltrials.​gov/​ct2/​show/​NCT02817997
Literature
1.
Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J (2015) Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 56:1252–1260PubMedCrossRef
2.
3.
Bonekamp D, Horton KM, Hruban RH, Fishman EK (2011) Castleman disease: the great mimic. Radiographics 31:1793–1807PubMedCrossRef
4.
Fajgenbaum DC, Uldrick TS, Bagg A et al (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129:1646–1657PubMedPubMedCentralCrossRef
5.
Jiang J-P, Shen X-F, Du J-F, Guan W-X (2018) A retrospective study of 34 patients with unicentric and multicentric Castleman’s disease: experience from a single institution. Oncol Lett 15:2407–2412PubMed
6.
Yu JY, Oh IJ, Kim KS et al (2014) Castleman’s disease presenting as a tracheal mass. Ann Thorac Surg 97:1798–1800PubMedCrossRef
7.
Ye B, Gao S-G, Li W et al (2010) A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol 27:1171–1178PubMedCrossRef
8.
Luo JM, Li S, Huang H et al (2015) Clinical spectrum of intrathoracic Castleman disease: a retrospective analysis of 48 cases in a single Chinese hospital. BMC Pulm Med 15:34PubMedPubMedCentralCrossRef
9.
Kligerman SJ, Auerbach A, Franks TJ, Galvin JR (2016) Castleman disease of the thorax: clinical, radiologic, and pathologic correlation: from the radiologic pathology archives. Radiographics 36:1309–1332PubMedCrossRef
10.
Cronin DMP, Warnke RA (2009) Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16:236PubMedCrossRef
11.
Madan R, Chen JH, Trotman-Dickenson B, Jacobson F, Hunsaker A (2012) The spectrum of Castleman’s disease: Mimics, radiologic pathologic correlation and role of imaging in patient management. Eur J Radiol 81:123–131PubMedCrossRef
12.
Delaney SW, Zhou S, Maceri D (2015) Castleman’s disease presenting as a parotid mass in the pediatric population: a report of 2 cases. Case Rep Otolaryngol 2015:691701PubMedPubMedCentral
13.
Oksenhendler E, Boutboul D, Fajgenbaum D et al (2018) The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 180:206–216PubMedCrossRef
14.
15.
Fajgenbaum DC, van Rhee F, Nabel CS (2014) HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 123:2924–2933PubMedCrossRef
16.
Powles T, Stebbing J, Bazeos A et al (2009) The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol 20:775–779PubMedCrossRef
17.
Zhang X, Rao H, Xu X et al (2018) Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients. Cancer Sci 109:199–206PubMedCrossRef
18.
Pria AD, Pinato D, Roe J, Naresh K, Nelson M, Bower M (2017) Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. Blood 129:2143–2147PubMedCrossRef
19.
Gérard L, Michot J-M, Burcheri S et al (2012) Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood Am Soc Hematol 119:2228–2233
20.
21.
Sitenga J, Aird G, Ahmed A, Silberstein PT (2018) Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease. Patient Relat Outcome Meas 9:35–41PubMedPubMedCentralCrossRef
22.
Suichi T, Misawa S, Sekiguchi Y et al (2020) Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. J Neurol Sci 413:116771PubMedCrossRef
23.
24.
Műzes G, Sipos F, Csomor J, Sréter L (2013) Multicentric Castleman’s disease: a challenging diagnosis. Pathol Oncol Res 19:345–351PubMedCrossRef
25.
Dispenzieri A (2019) POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 94:812–827PubMed
26.
27.
van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z (2010) Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 8:486–498PubMed
28.
Polizzotto MN, Uldrick TS, Wang V et al (2013) Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 122:4189–4198PubMedPubMedCentralCrossRef
29.
Suthaus J, Stuhlmann-Laeisz C, Tompkins VS et al (2012) HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 119:5173–5181PubMedPubMedCentralCrossRef
30.
Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ (2008) HIV-associated multicentric Castleman’s disease. Am J Hematol 83:498–503PubMedCrossRef
31.
32.
33.
Waterston A, Bower M (2004) Fifty years of multicentric Castleman’s disease. Acta Oncol 43:698–704PubMedCrossRef
34.
Hill AJ, Tirumani SH, Rosenthal MH et al (2015) Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol 88:20140670PubMedPubMedCentralCrossRef
35.
Savelli G, Muni A, Falchi R, Giuffrida F (2015) Pre- and post-therapy 18F-FDG PET/CT of a patient affected by non-HIV multicentric IgG4-related Castleman disease. Blood Res 50:260–262PubMedPubMedCentralCrossRef
36.
van Rhee F, Voorhees P, Dispenzieri A et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132:2115–2124PubMedPubMedCentralCrossRef
37.
Kwon S, Lee KS, Ahn S, Song I, Kim TS (2013) Thoracic Castleman disease: computed tomography and clinical findings. J Comput Assist Tomogr 37:1–8PubMedCrossRef
38.
Lee ES, Paeng JC, Park CM et al (2013) Metabolic characteristics of castleman disease on 18F-FDG PET in relation to clinical implication. Clin Nucl Med 38:339–342PubMedCrossRef
39.
Barker R, Kazmi F, Stebbing J et al (2009) FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease. Eur J Nucl Med Mol Imaging 36:648–652PubMedCrossRef
40.
Balamoutoff N, Serrano B, Hugonnet F, Garnier N, Paulmier B, Faraggi M (2018) Added value of a single fast 20-second deep-inspiration breath-hold acquisition in FDG PET/CT in the assessment of lung nodules. Radiology 286:260–270PubMedCrossRef
41.
Flavell RR, Behr SC, Mabray MC, Hernandez-Pampaloni M, Naeger DM (2016) Detecting pulmonary nodules in lung cancer patients using whole body FDG PET/CT, high-resolution lung reformat of FDG PET/CT, or diagnostic breath hold chest CT. Acad Radiol 23:1123–1129PubMedCrossRef
42.
Liu C, Alessio AM, Kinahan PE (2011) Respiratory motion correction for quantitative PET/CT using all detected events with internal-external motion correlation. Med Phys 38:2715–2723PubMedPubMedCentralCrossRef
43.
Büther F, Jones J, Seifert R, Stegger L, Schleyer P, Schäfers M (2020) Clinical evaluation of a data-driven respiratory gating algorithm for whole-body PET with continuous bed motion. J Nucl Med 61:1520–1527PubMedCrossRef
44.
Kim JS, Lim ST, Jeong YJ, Kim DW, Jeong HJ, Sohn MH (2010) F-18 FDG PET/CT for the characterization of Castleman’s disease according to clinical subtype. J Nucl Med 51:1614–1614
45.
Rassouli N, Obmann VC, Sandhaus LM, Herrmann KA (2018) (18F)-FDG-PET/MRI of unicentric retroperitoneal Castleman disease in a pediatric patient. Clin Imaging 50:175–180PubMedCrossRef
46.
47.
Raynor WY, Borja AJ, Rojulpote C, Høilund-Carlsen PF, Alavi A. 18F-sodium fluoride: An emerging tracer to assess active vascular microcalcification. J Nucl Cardiol. 2020;
48.
Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354CrossRefPubMed
49.
Graham MM, Wahl RL, Hoffman JM et al (2015) Summary of the UPICT protocol for 18F-FDG PET/CT imaging in oncology clinical trials. J Nucl Med 56:955–961PubMedCrossRef
50.
51.
Fu Z, Zhang X, Fan Y, Di L, Zhang J, Wang RF (2013) Clinical value of 18F-FDG PET/CT in the management of Castleman’s disease. J Nucl Med 54:1560–1560
52.
Murphy SP, Nathan MA, Karwal MW (1997) FDG-PET appearance of pelvic Castleman’s disease. J Nucl Med 38:1211–1212PubMed
53.
Haap M, Wiefels J, Horger M, Hoyer A, Müssig K (2018) Clinical, laboratory and imaging findings in Castleman’s disease—the subtype decides. Blood Rev 32:225–234PubMedCrossRef
54.
Mohammed A, Janku F, Qi M, Kurzrock R (2015) Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report. J Med Case Rep 9:45PubMedPubMedCentralCrossRef
55.
Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (2014) Peripheral lymphadenopathy: approach and diagnostic tools. Iran J Med Sci 39:158–170PubMedPubMedCentral
56.
57.
58.
Fajgenbaum DC, Langan R-A, Japp AS et al (2019) Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129:4451–4463PubMedPubMedCentralCrossRef
59.
Elboga U, Narin Y, Urhan M, Sahin E (2012) FDG PET/CT appearance of multicentric Castleman’s disease mimicking lymphoma. Rev Esp Med Nucl Imagen Mol 31:142–144PubMed
60.
Akosman C, Selcuk NA, Ordu C, Ercan S, Ekici ID, Oyan B (2011) Unicentric mixed variant Castleman disease associated with Hashimoto disease: the role of PET/CT in staging and evaluating response to the treatment. Cancer Imaging 11:52–55PubMedPubMedCentral
61.
Casper C (2005) The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 129:3–17PubMedCrossRef
62.
63.
van Rhee F, Greenway A, Stone K (2018) Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am 32:89–106PubMedCrossRef
64.
65.
Pelosi E, Skanjeti A, Cistaro A, Arena V (2008) Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman’s disease: a case report. J Med Case Rep 2:99PubMedPubMedCentralCrossRef
66.
Jain L, Mackenzie S, Bomanji JB et al (2018) 18F-Fluorodeoxyglucose positron emission tomography-computed tomography imaging in HIV-infected patients with lymphadenopathy, with or without fever and/or splenomegaly. Int J STD AIDS 29:691–694PubMedCrossRef
67.
Diéval C, Bonnet DF, Mauclère S et al (2007) Multicentric Castleman disease: Use of HHV8 viral load monitoring and positron emission tomography during follow-up. Leuk Lymphoma 48:1881–1883PubMedCrossRef
68.
Sanz-Viedma S, Torigian DA, Parsons M, Basu S, Alavi A (2009) Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging. Rev Esp Med Nucl 28:159–166PubMedCrossRef
69.
Borja A, Aly M, Seraj SM et al (2020) Role of FDG in the management of metastatic hepatic tumors treated with chemoembolization. J Nucl Med Soc Nuclear Med 61:1181–1181
70.
Cheng G, Torigian DA, Zhuang H, Alavi A (2013) When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging 40:779–787PubMedCrossRef
71.
Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A (2011) A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging 38:1158–1170PubMedCrossRef
72.
Sarikaya I, Sarikaya A (2020) Assessing PET parameters in oncologic 18F-FDG studies. J Nucl Med Technol 48:278–282PubMedCrossRef
73.
Kang F, Han Q, Zhou X et al (2020) Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu’s arteritis patients. Eur J Nucl Med Mol Imaging 47:3107–3117PubMedCrossRef
74.
75.
Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R (2017) EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 44:17–31PubMedPubMedCentralCrossRef
76.
Davis JC, Daw NC, Navid F et al (2018) 18F-FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. J Nucl Med 59:25–30PubMedPubMedCentralCrossRef
77.
Im H-J, Zhang Y, Wu H et al (2018) Prognostic value of metabolic and volumetric parameters of FDG pet in pediatric osteosarcoma: a hypothesis-generating study. Radiology 287:303–312PubMedCrossRef
78.
Basu S, Zaidi H, Salavati A, Hess S, Høilund-Carlsen PF, Alavi A (2014) FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and “semiquantitative SUVmax” to global disease burden assessment. Eur J Nucl Med Mol Imaging 41:2158–2160PubMedCrossRef
79.
Taghvaei R, Zadeh MZ, Oestergaard B et al (2017) PET imaging in hematological malignancies. J Nucl Med 58:1008–1008
80.
Raynor WY, Zadeh MZ, Kothekar E, Yellanki DP, Alavi A (2019) Evolving role of PET-based novel quantitative techniques in the management of hematological malignancies. PET Clin 14:331–340PubMedCrossRef
81.
Borja AJ, Hancin EC, Zhang V, Revheim M-E, Alavi A (2020) Potential of PET/CT in assessing dementias with emphasis on cerebrovascular disorders. Eur J Nucl Med Mol Imaging 47:2493–2498PubMedCrossRef
82.
Kothekar E, Yellanki D, Borja AJ et al (2020) 18F-FDG-PET/CT in measuring volume and global metabolic activity of thigh muscles: a novel CT-based tissue segmentation methodology. Nucl Med Commun 41:162–168PubMedCrossRef
83.
Borja AJ, Hancin EC, Dreyfuss AD et al (2020) 18F-FDG-PET/CT in the quantification of photon radiation therapy-induced vasculitis. Am J Nucl Med Mol Imaging 10:66–73PubMedPubMedCentral
84.
Sun L, Sun X, Li Y, Xing L (2015) The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor. Onco Targets Ther 8:1967–1970PubMedPubMedCentralCrossRef
85.
Graf N, Li Z, Herrmann K et al (2014) Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. Onco Targets Ther 7:789–798PubMedPubMedCentral
86.
Owonikoko TK (2015) Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs. Cancer 121:3390–3392PubMedCrossRef
87.
Anwar H, Sachpekidis C, Schwarzbach M, Dimitrakopoulou-Strauss A (2017) Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: response to mammalian target of rapamycin inhibitor therapy. Hell J Nucl Med 20:169–171PubMed
Metadata
Title
Emerging role of 18F-FDG PET/CT in Castleman disease: a review
Authors
Benjamin Koa
Austin J. Borja
Mahmoud Aly
Sayuri Padmanabhan
Joseph Tran
Vincent Zhang
Chaitanya Rojulpote
Sheila K. Pierson
Mark-Avery Tamakloe
Johnson S. Khor
Thomas J. Werner
David C. Fajgenbaum
Abass Alavi
Mona-Elisabeth Revheim
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Insights into Imaging / Issue 1/2021
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-021-00963-1

Other articles of this Issue 1/2021

Insights into Imaging 1/2021 Go to the issue

Original Article

Standardisation of prostate multiparametric MRI across a hospital network: a London experience

Statement

ESR white paper: blockchain and medical imaging

Original Article

Fully automated pelvic bone segmentation in multiparameteric MRI using a 3D convolutional neural network

Statement

The current status of uptake of European Basic Safety Standard (2013/59/Euratom) requirements: results of a follow-up survey in European radiology departments

Original Article

The role of CT imaging for management of COVID-19 in epidemic area: early experience from a University Hospital

Original Article

Quantitative analysis of metal artifact reduction in total hip arthroplasty using virtual monochromatic imaging and orthopedic metal artifact reduction, a phantom study